WallStSmart

HCA Healthcare, Inc. (HCA)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HCA Healthcare, Inc. generates 17% more annual revenue ($78.01B vs $66.57B). HCA leads profitability with a 8.8% profit margin vs 4.8%. HCA appears more attractively valued with a PEG of 1.29. HCA earns a higher WallStSmart Score of 65/100 (C+).

HCA

Buy

65

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 5.3Quality: 6.0
Piotroski: 5/9Altman Z: 1.71

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HCASignificantly Overvalued (-76.3%)

Margin of Safety

-76.3%

Fair Value

$301.38

Current Price

$438.12

$136.74 premium

UndervaluedFair: $301.38Overvalued
MRKSignificantly Overvalued (-77.2%)

Margin of Safety

-77.2%

Fair Value

$83.04

Current Price

$150.91

$67.87 premium

UndervaluedFair: $83.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCA5 strengths · Avg: 9.0/10
Return on EquityProfitability
136.3%10/10

Every $100 of equity generates 136 in profit

Debt/EquityHealth
-7.4210/10

Conservative balance sheet, low leverage

Market CapQuality
$92.43B9/10

Large-cap with strong market position

P/E RatioValuation
14.3x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.10B8/10

Generating 1.1B in free cash flow

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

HCA1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.9x4/10

Trading at 8.9x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : HCA

The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : HCA

The primary concerns for HCA are Altman Z-Score.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

HCA carries more volatility with a beta of 1.11 — expect wider price swings.

HCA is growing revenue faster at 8.7% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HCA scores higher overall (65/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

HCA Healthcare, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?